FBT News and Press, First Trust Amex Biotech Index Fund From 05/05/22

FBT doesn’t pay any dividend and had a negative price growth over the short term. Barring the inverse funds, all other biotechnology ETFs had a high negative growth over the past 12 months. FBT’s price multiples are around category average, and current price is quite...

KPTI has been devastated by the SIENDO trial failure. The next trial's data will be read out 2 years later. Until then, I see little upside for the stock. For further details see: Karyopharm: Another 2 Year Wait For Data

MorphoSys stock has taken a huge hit since its Constellation buyout. The company has staked an entire existing revenue stream for a development stage asset. The market hasn't taken this kindly. For further details see: MorphoSys May Not Recover From Adventurous Constella...

During the last Fed rate raising cycle, it took the Federal Reserve five years to raise the fed funds rate to 2.50%. The Fed kept rates far too low for far too long and now we are dealing with the consequences. Both fiscal and monetary policy have been highly inflationary, and we are ...

Biotechnology exchange traded fund SPDR S&P Biotech ETF (NYSEARCA:XBI) hovers near its one-year trading low, but the investment community has shown recent interest in the fund as the ETF has experienced a large influx of capital in 2022. While XBI trades down 27% on the yea...

Since the beginning of COVID-19, companies and countries have struggled to ensure steady supply of key inputs to the normal functioning of our economies. Synthetic biology is a revolutionary technology that could make a profound impact on the way a vast array of products are manufactu...

Typically, we look at net new highs as a way to confirm moves in the broader market. At the high last Wednesday, over 90% of S&P 500’s new highs came from defensive sectors. In other words, defensives have been a notable pocket of strength recently. For further de...

Stock markets fell in the first quarter as Russia’s invasion of Ukraine destabilized the growth outlook, amplified concerns about rising interest rates and unleashed geopolitical risks. While the conflict has created many uncertainties, we believe the impact of persistent infla...

GNOM lacks efficient portfolio reshuffling and may not be able to gain from higher alpha-producing stocks in the near future. Despite being a ‘Genomic Revolution’ fund, it lacks focus, and invested heavily on large cap diverse biotechnology companies. Better ‘...

The SPDR S&P Biotech ETF (NYSEARCA:XBI) is on pace for its best trading week in 21 months as the exchange traded fund earlier this week hit a 23-month trading low. XBI is now +8.2% and +2.6% for the day. The biotech fund had not seen such bullish weekly moves since Jun...